038290 Macrogen

Macrogen Launches Special Promotion on Exome Sequencing to Celebrate Their 20th Anniversary

SEOUL, South Korea--(BUSINESS WIRE)--

Macrogen Inc. (CEO Hyon-yong Chong, www.macrogen.com) (KOSDAQ:038290), a precision medicine biotechnology company, announced on June 1st that it is launching a special promotion on Exome Sequencing to celebrate their 20th anniversary.

During this special promotion period, Macrogen will offer Exome Sequencing service with 100x coverage using SureSelect Human All Exon V5 (50M) or V6 (58M) capture kit at a special price of $299 per sample. This is an innovative price that has never been offered anywhere else before. Through this promotion, researchers around the world can take advantage of Macrogen’s Exome service that is known for its high-quality data and fast Turnaround Time (TAT) on very special price terms.

Macrogen has obtained the highest level of genome analysis technology in the world through continuous technological development and research activities for the past 20 years. In 2016, Macrogen established the world's highest-precision reference of a Korean genome (Nature, 2016) and has since been recognized globally for its outstanding academic capacity and technology. Furthermore, in order to strengthen its position as the technological leader, Macrogen purchased the latest sequencing equipment, NovaSeq6000 (Illumina Inc.). This enables Macrogen to analyze over 70,000 human genomes, or 8,000Tb per year.

Macrogen’s CEO Hyon-yong Chong said, "This Exome promotion is not only to celebrate the 20th anniversary of Macrogen, but is also to satisfy our customers with its competitive edge in low price and top-notch analytical service." Chong added, "Macrogen will always strive to provide services that our customers can value."

For further details on this promotion, please refer to below link:

http://dna.macrogen.com/eng/support/event/event_view.jsp?board_number=26475

For details on service and ordering, please contact [email protected].

About Macrogen

Macrogen is a leading service provider of integrated genomic research dedicated to providing the highest quality genomics services. Macrogen provide a wide range of sequencing and bioinformatics services to the academic, pharmaceutical, and clinical research communities around the world. For more information on Macrogen, please visit www.macrogen.com.

EN
02/06/2017

Underlying

038290Macrogen

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Macrogen

 PRESS RELEASE
Free
038290 MACROGEN

Macrogen Licenses Gene Editing Technology from Broad Institute of MIT ...

SEOUL, South Korea--(BUSINESS WIRE)-- Macrogen, Inc. (CEO Ji-young Moon, www.macrogen.com) (KOSDAQ: 038290), a precision medicine biotechnology company, announced on April 5 that it has acquired a non-exclusive commercial research tool license to CRISPR-Cas9 technology from the Broad Institute of MIT and Harvard in the USA, and said that the company’s gene editing technical portfolio has been further strengthened by licensing of this technology. Macrogen has acquired around 50 technologies, including the CRISPR-Cas9 portfolio...

April 5, 2018 1 EN
 PRESS RELEASE
Free
038290 MACROGEN

Macrogen Corp.'s Clinical NGS Laboratory Receives CAP Accreditation

ROCKVILLE, Md.--(BUSINESS WIRE)-- Macrogen Corp. (www.macrogenlab.com) announces that its Clinical Lab that provides clinical NGS services has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP) based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs. “Macrogen demonstrates leadership, innovation, and a passionate commitment to standards of excellence while providing the highest quality services, ultimately for patients,” said Bharati Jhav...

November 15, 2017 1 EN
 PRESS RELEASE
Free
038290 MACROGEN

Le laboratoire d’analyses NGS de Macrogen Corp. reçoit l’accré...

ROCKVILLE, Maryland--(BUSINESS WIRE)-- Macrogen Corp. (www.macrogenlab.com) annonce que son laboratoire d’analyses qui fournit des services cliniques NGS a été accrédité par le Comité d’accréditation du College of American Pathologists (CAP), suite aux résultats d’une récente inspection effectuée sur place dans le cadre des Programmes d’accréditation, du CAP. « Macrogen témoigne de son leadership, de ses innovations et de son engagement passionné à respecter les normes d’excellence tout en fournissant des services de q...

November 15, 2017 1 FR
 PRESS RELEASE
Free
038290 MACROGEN

Macrogen Established Its Branch in Spain, Strengthening Localization S...

SEOUL, South Korea--(BUSINESS WIRE)-- Macrogen Inc. (CEO Hyon-yong Chong, www.macrogen.com) (KOSDAQ:038290), a precision medicine biotechnology company, announced on Sept. 4 that it will begin providing localization service in September at its branch in Madrid, Spain. The Spanish branch of Macrogen was established last December following its first European branch in Amsterdam, Netherlands. This branch will provide quick and customer-friendly services to Southern Europe and the MENA (Middle East and North Africa) area t...

September 4, 2017 1 EN
 PRESS RELEASE
Free
038290 MACROGEN

Macrogen a établi une succursale en Espagne, afin de renforcer son se...

SÉOUL, Corée du Sud--(BUSINESS WIRE)-- Macrogen Inc. (CEO Hyon-yong Chong, www.macrogen.com) (KOSDAQ : 038290), une société de biotechnologie médicale de précision, a annoncé le 4 septembre que dès septembre elle offrirait, depuis sa succursale de Madrid en Espagne, un service de localisation. La succursale espagnole de Macrogen a été créée en décembre dernier après l’ouverture de sa première branche européenne à Amsterdam, aux Pays-Bas. Cette succursale fournira des services rapides et adaptés aux clients du sud de ...

September 4, 2017 1 FR

ResearchPool Subscriptions

Get the most out of your insights

Get in touch